DE69918283D1 - Stabilisierte herpesvirusformulierung - Google Patents

Stabilisierte herpesvirusformulierung

Info

Publication number
DE69918283D1
DE69918283D1 DE69918283T DE69918283T DE69918283D1 DE 69918283 D1 DE69918283 D1 DE 69918283D1 DE 69918283 T DE69918283 T DE 69918283T DE 69918283 T DE69918283 T DE 69918283T DE 69918283 D1 DE69918283 D1 DE 69918283D1
Authority
DE
Germany
Prior art keywords
herpesvirus
stabilized
virus
formulation
aminoacids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918283T
Other languages
English (en)
Other versions
DE69918283T2 (de
Inventor
Alison Varley
Thomas Loudon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Pharmaceuticals Research Ltd
Original Assignee
Cantab Pharmaceuticals Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research Ltd filed Critical Cantab Pharmaceuticals Research Ltd
Publication of DE69918283D1 publication Critical patent/DE69918283D1/de
Application granted granted Critical
Publication of DE69918283T2 publication Critical patent/DE69918283T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE1999618283 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung Expired - Fee Related DE69918283T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808922 1998-04-24
GB9808922A GB9808922D0 (en) 1998-04-24 1998-04-24 Virus preparations
PCT/GB1999/001295 WO1999055348A2 (en) 1998-04-24 1999-04-26 Stabilised virus preparation

Publications (2)

Publication Number Publication Date
DE69918283D1 true DE69918283D1 (de) 2004-07-29
DE69918283T2 DE69918283T2 (de) 2005-07-21

Family

ID=10831020

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999618283 Expired - Fee Related DE69918283T2 (de) 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung

Country Status (12)

Country Link
US (1) US6258362B1 (de)
EP (1) EP1071438B1 (de)
JP (1) JP2002512970A (de)
AT (1) ATE269712T1 (de)
AU (1) AU3718299A (de)
CA (1) CA2329000C (de)
DE (1) DE69918283T2 (de)
DK (1) DK1071438T3 (de)
ES (1) ES2224646T3 (de)
GB (1) GB9808922D0 (de)
PT (1) PT1071438E (de)
WO (1) WO1999055348A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US20040022800A1 (en) * 2000-07-31 2004-02-05 Mark Parrington Respiratory syncytial virus vaccine
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
KR20040074067A (ko) * 2001-12-10 2004-08-21 버베리안 노딕 에이/에스 폭스바이러스를 포함하는 제형 및 폭스바이러스를포함하는 안정한 조성물을 제조하기 위한 방법
AU2008201215B2 (en) * 2001-12-10 2010-11-18 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
JP4495143B2 (ja) * 2003-02-20 2010-06-30 セントロ ナショナル デ インヴェスティゲーションズ シエンティフィカス（セーエネイーセー） 生物学的安全性が向上した経口ワクチン接種用凍結乾燥形態のコレラ菌弱毒化株
JP2007517888A (ja) * 2004-01-15 2007-07-05 インターベツト・インターナシヨナル・ベー・ベー 非動物由来安定剤およびその製造方法
US8916175B2 (en) * 2004-06-29 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection
MX2007005379A (es) * 2004-11-05 2007-07-04 Wellstat Biologics Corp Formulaciones de virus envueltos estables y filtrables.
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
US20070031450A1 (en) * 2005-08-04 2007-02-08 Wyeth Stabilizers for veterinary vaccines
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US10166285B2 (en) 2006-11-09 2019-01-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant virus with diminished latency and methods of using same
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
EP2351849A4 (de) * 2008-10-17 2013-10-30 Tokyo University Of Marine Science And Technology Reagenzienkit zur frischemessung
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
WO2010138522A2 (en) * 2009-05-26 2010-12-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US8834951B2 (en) 2010-01-28 2014-09-16 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
WO2012021783A2 (en) 2010-08-13 2012-02-16 Advanced Bionutrition Corporation Dry storage stabilizing composition for biological materials
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
WO2013106398A1 (en) 2012-01-09 2013-07-18 Sanofi Pasteur Biologics, Llc Purification of herpes virus
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
FR3024780B1 (fr) * 2014-08-07 2018-11-30 Bertin Pharma Reactif pret a l'emploi
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2020113197A1 (en) * 2018-11-30 2020-06-04 Vaccine Stabilization Institute Viral formulations containing amino acids
CA3124690A1 (en) 2018-12-27 2020-07-02 Amgen Inc. Lyophilized virus formulations
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209738C (de)
GB960850A (en) * 1961-09-08 1964-06-17 Wellcome Found Measles virus vaccine
JPS4848621A (de) * 1971-10-20 1973-07-10
JPS4868730A (de) * 1971-12-21 1973-09-19
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5648488B2 (de) * 1973-06-06 1981-11-16
JPS5341202B2 (de) * 1974-03-12 1978-11-01
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
AU532186B2 (en) * 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0048194A3 (de) * 1980-08-28 1982-09-01 Merck & Co. Inc. Verfahren zur Lyophilisierung
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
HU183765B (en) * 1981-12-23 1984-05-28 Phylaxia Oltoanyagtermeloe Process for producing lyophilized vaccine against duck hepatitis
ZA874625B (en) 1986-06-30 1988-10-26 Smith Kline Rit Stabilizers for live vaccines,process for their preparation and vaccines containing them
JPS63230851A (ja) * 1987-03-20 1988-09-27 Sumitomo Metal Ind Ltd 耐食性に優れた油井管用低合金鋼
IE61575B1 (en) 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
FR2633518B1 (fr) 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
CA2132328C (en) 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
JPH06234659A (ja) 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
WO1993024616A1 (en) * 1992-06-04 1993-12-09 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
EP0689603A1 (de) 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff
JPH09504429A (ja) * 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
WO1996029096A1 (en) 1995-03-17 1996-09-26 Hisamitsu Pharmaceutical Co., Inc. Gene transfer preparation
JP2000507963A (ja) 1996-12-20 2000-06-27 メルク エンド カンパニー インコーポレーテッド 凍結乾燥ワクチン用安定剤

Also Published As

Publication number Publication date
WO1999055348A2 (en) 1999-11-04
CA2329000C (en) 2010-03-23
ES2224646T3 (es) 2005-03-01
DE69918283T2 (de) 2005-07-21
ATE269712T1 (de) 2004-07-15
US6258362B1 (en) 2001-07-10
WO1999055348A3 (en) 1999-12-16
DK1071438T3 (da) 2004-10-25
GB9808922D0 (en) 1998-06-24
JP2002512970A (ja) 2002-05-08
PT1071438E (pt) 2004-11-30
CA2329000A1 (en) 1999-11-04
EP1071438B1 (de) 2004-06-23
EP1071438A2 (de) 2001-01-31
AU3718299A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
DE69918283D1 (de) Stabilisierte herpesvirusformulierung
IL124941A0 (en) Formulations of nerve growth factor suitable for lyophilization
MX9604907A (es) Vacuna de combinacion de virus para la enfermedad de newcastle.
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
NO20010576L (no) Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav
AU1198697A (en) Stabilizers for live vaccines
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
PT1140165E (pt) Composições de adjuvante de saponina melhoradas e métodos relacionados
AU2497292A (en) Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
AU1271799A (en) Methods for preventing and treating bacterial infections using cellulose ace tatephthalate or hydroxypropyl methylcellulose phthalate excipients
IL133220A0 (en) Stabilized antibody formulation
IL201429A (en) Weakened live virus compositions and methods to reduce disabling live viruses
NO985094D0 (no) Polymerpulver som er redispergerbart i vandige l°sninger
AU4622693A (en) Potentiation of immunogenic response
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
DE69928921D1 (de) Vormischungszusammensetzung zur bierklärung
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ES2056042T1 (es) Copolimeros solubles en agua de acetato de vinilo y acido maleamico. uso como fluidizadores o reductores de agua de alto alcance para suspensiones acuosas.
EP1420802A4 (de) Erhöhte löslichkeit von flavanolignan-zubereitungen
CO5280138A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para en vacas gestantes
EP1105157A4 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee